ESMO Asia Virtual Congress 2020: Meeting Resources

Systemic inflammation is a key driver of mortality in SARS-CoV-2 in cancer patients and biomarkers of inflamation may be used to identify patients at increased risk

Innovative risk-assessment tool measures the patient’s local immune response to the tumour

All of the pembrolizumab regimens were safe in patients with metastatic castration-resistant prostate cancer

KEYNOTE-426 data from patients enrolled in Eastern Asia is consistent with that of the overall population

Safety has already been demonstrated for sintilimab, a monoclonal antibody targeting the PD-1, plus a bevacizumab biosimilar as first-line treatment for advanced hepatocellular carcinoma

Improved outcomes following first-line CS1001/chemotherapy were observed in Chinese patients with both squamous and non-squamous histology

Efficacy of the irreversible pan-HER tyrosine kinase inhibitor, neratinib, consistent with the results in the overall NALA population

Findings at 4-year follow-up in East Asian patients with advanced HR-positive, HER2-negative breast cancer are consistent with those in the overall MONARCH 2 study population

The most widely used therapies and subsequent outcomes were identified with the aim of informing T-cell lymphoma treatment

Data from the subgroup of patients from Asia-Pacific with pretreated triple negative breast cancer were similar to that observed in overall KEYNOTE-119 study population

The Japan subset showed similar progression-free survival to the overall PAOLA-1 population

Chinese patients receiving niraparib, a potent inhibitor of PARP 1/2, benefited from an individualised starting dose

Findings from a first phase II study of this combination in nasopharyngeal carcinoma

Patients enrolled from Asia demonstrated consistent findings with those in the overall population of the KEYNOTE-355 study

Subgroup of Asian patients with triple negative breast cancer demonstrates similar reponse as observed in patients overall in the KEYNOTE-522 study

The benefits in patients with advanced ovarian cancer and a BRCA mutation lasted well-beyond the two-year olaparib maintenance treatment

Findings of the Chinese phase II study with novel, orally administered tyrosine kinase inhibitor

Envafolimab provided responses across various tumour types

The non-invasive ELSA-seq blood-based methylation sequencing assay demonstrated sensitivity and specificity

Intrahepatic cholangiocarcinoma has a higher incidence in Asian than in Western countries and carries a poor prognosis

Characteristics of patients from Asia enrolled in monarchE study